Literature DB >> 19023522

Risk stratification for venous thromboembolism in hospitalized patients in a developing country: a prospective study.

Abdallah Awidi1, Nathir Obeidat, Ahmad Magablah, Nazzal Bsoul.   

Abstract

Venous Thrombo-Embolism (VTE) is a serious complication in hospitalized patients but can be preventable. This prospective study addresses risk factors assessment and the use of heparin in this population. About 2,496 non pediatric patients were admitted to Jordan University Hospital between June 12, 2007 and July 19, 2007. A random sample of 624 patients consisting of every fourth admission was chosen. The stratification of risk factors was assessed using Caprini model and the ACCP score. The mean age of the patients (229 males and 395 females) was 45.34 +/- 18.3 years. More than 80% of the admitted patients were considered at high risk for VTE but heparin was used in only 26% of the patients. The majority of our patients constitute a high-risk population. Implementation of strategies including educational sessions and risk stratification guidelines can reduce the incidence, morbidity, and mortality of VTE especially in developing countries.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19023522     DOI: 10.1007/s11239-008-0291-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  19 in total

Review 1.  Risk factors for venous thrombotic disease.

Authors:  F R Rosendaal
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

2.  High prevalence of factor V Leiden in healthy Jordanian Arabs.

Authors:  A Awidi; M Shannak; A Bseiso; M A Kailani; M A Kailani; N Omar; B Anshasi; N Sakarneh
Journal:  Thromb Haemost       Date:  1999-04       Impact factor: 5.249

3.  Results of the national pilot screening program for venous disease by the American Venous Forum.

Authors:  Robert B McLafferty; Joanne M Lohr; Joseph A Caprini; Marc A Passman; Frank T Padberg; Thom W Rooke; Ruth L Bush; Aamir A Zakaria; William R Flinn; Bo G Eklof; Michael C Dalsing; Steven J Markwell; Thomas W Wakefield
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

4.  Factor V R506Q mutation-Leiden: an independent risk factor for venous thrombosis but not coronary artery disease.

Authors:  N Irani-Hakime; H Tamim; G Elias; S Choueiry; R Kreidy; J L Daccache; W Y Almawi
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

5.  Incorrect use of thromboprophylaxis for venous thromboembolism in medical and surgical patients: results of a multicentric, observational and cross-sectional study in Brazil.

Authors:  D Deheinzelin; A L Braga; L C Martins; M A Martins; A Hernandez; W B Yoshida; F Maffei; M Monachini; D Calderaro; W Campos; G T Sguizzatto; B Caramelli
Journal:  J Thromb Haemost       Date:  2006-06       Impact factor: 5.824

Review 6.  Venous thromboembolism: disease burden, outcomes and risk factors.

Authors:  J A Heit
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

Review 7.  Venous thrombosis: a multicausal disease.

Authors:  F R Rosendaal
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

8.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Clive Kearon; Susan R Kahn; Giancarlo Agnelli; Samuel Goldhaber; Gary E Raskob; Anthony J Comerota
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Venous thrombosis in cancer patients: insights from the FRONTLINE survey.

Authors:  Ajay K Kakkar; Mark Levine; H M Pinedo; Robert Wolff; John Wong
Journal:  Oncologist       Date:  2003

Review 10.  Risk factors for venous thromboembolism.

Authors:  Frederick A Anderson; Frederick A Spencer
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

View more
  7 in total

1.  Practice guidelines and clinical risk assessment models: is it time to reform?

Authors:  Nariman Sepehrvand; Firouz Ghaderi Pakdel; Mohammad Hosein Rahimi-Rad; Babak Moosavi-Toomatari; Shahrzad Bazargan-Hejazi
Journal:  BMC Med Inform Decis Mak       Date:  2011-10-18       Impact factor: 2.796

2.  Evaluation of venous thromboembolism prophylaxis in a major hospital in a developing country.

Authors:  Lubna Gharaibeh; Hanan Sartawi; Diana Ayyad; Tareq Juma; Kamal Albassoumi; Enas Ismail
Journal:  Int J Clin Pharm       Date:  2017-06-16

3.  The AVAIL ME study: a multinational survey of VTE risk and prophylaxis.

Authors:  Ali T Taher; Joseph Aoun; Pascale Salameh
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

Review 4.  Diet as prophylaxis and treatment for venous thromboembolism?

Authors:  David K Cundiff; Paul S Agutter; P Colm Malone; John C Pezzullo
Journal:  Theor Biol Med Model       Date:  2010-08-11       Impact factor: 2.432

5.  Antithrombotic prophylaxis in the middle East.

Authors:  Samir Arnaout; Hanady R Samaha; Julien Succar; Imad Bou-Akl; Khaled M Musallam; Ali T Taher
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-05-24       Impact factor: 2.576

6.  A cross-sectional, multicenter, observational study to assess the prophylaxis of venous thromboembolism in Lebanese and Jordanian hospitals.

Authors:  Imad Hajj; Mahmoud Al-Masri; Kaldoun Bashaireh; Mohammed Bani Hani; Shadi Hamouri; Joe Khouzami; Nisrine Sabra; Chahine Fadel
Journal:  Thromb J       Date:  2021-02-10

7.  Evaluation of venous thromboembolism (VTE) risk assessment and thrombo-prophylaxis practices in hospitalized medical and surgical patients at Aga Khan Hospital Dar es Salaam: single-centre retrospective study.

Authors:  Allyzain Ismail; Nikhil Jadawji; Philip Adebayo; Ahmed Jusabani; Kamran Hameed; Ali Akbar Zehri; Willy Kiviri; Athar Ali
Journal:  Pan Afr Med J       Date:  2022-06-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.